Onsdag 18 November | 10:32:55 Europe / Stockholm
Est. tid*
2026-11-13 - Kvartalsrapport 2026-Q3
2026-08-27 - Kvartalsrapport 2026-Q2
2026-05-21 - Kvartalsrapport 2026-Q1
2026-04-15 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2026-04-14 - Årsstämma
2026-02-12 - Bokslutskommuniké 2025
2026-01-26 - Extra Bolagsstämma 2026
2025-11-18 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-30 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2024
2024-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-22 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Lytix Biopharma ASA: Ex. subsequent offering

2026-11-18 02:05:59

Oslo, Norway, 18 November 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma ASA ("Lytix Biopharma" or the "Company") today regarding the successful completion of a private placement (the "Private Placement") and a retail offering (the "Retail Offering") of new shares (the "Offer Shares") raising NOK 80 million in gross proceeds, and a subsequent offering of new shares, at the same price as in the Private Placement and Retail Offering, NOK 8.00 per share (the "Subsequent Offering").

The Subsequent Offering will be directed towards existing shareholders in the Company as of 17 November 2026 (as registered in the VPS on 19 November 2026), subject to the limitations and conditions set out in the stock exchange announcement including key information about the Subsequent Offering. The shares in Lytix Biopharma will accordingly be traded exclusive of the right to participate in the Subsequent Offering from and including today.

Ex. date: 18 November 2026

This information is published in accordance with the requirements of the Continuing Obligations.

For further information, please contact:

Gjest Breistein, CFO

gjest.breistein@lytixbiopharma.com

+47 952 60 512

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to effectively prime durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker LYTIX.